May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Topical Cyclosporine a 2% in Patients With Severe Ocular Rosacea After Penetrating Keratoplasty: A 3 Years Follow-Up
J.-J. Gicquel; J.-L. Bourges; J.-G. Bonneric; R. A. Bejjani; M. Langman; G. Renard; P. Dighiero
Author Affiliations & Notes
  • J.-J. Gicquel
    Ophthalmology, Jean Bernard University Hospital, Poitiers, France
  • J.-L. Bourges
    Ophthalmology, Hôtel Dieu, Paris, France
  • J.-G. Bonneric
    Ophthalmology, Jean Bernard University Hospital, Poitiers, France
  • R. A. Bejjani
    Ophthalmology, Jean Bernard University Hospital, Poitiers, France
  • M. Langman
    Ophthalmology, Jean Bernard University Hospital, Poitiers, France
  • G. Renard
    Ophthalmology, Hôtel Dieu, Paris, France
  • P. Dighiero
    Ophthalmology, Jean Bernard University Hospital, Poitiers, France
  • Footnotes
    Commercial Relationships J. Gicquel, None; J. Bourges, None; J. Bonneric, None; R.A. Bejjani, None; M. Langman, None; G. Renard, None; P. Dighiero, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4274. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Topical Cyclosporine a 2% in Patients With Severe Ocular Rosacea After Penetrating Keratoplasty: A 3 Years Follow-Up
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J.-J. Gicquel, J.-L. Bourges, J.-G. Bonneric, R. A. Bejjani, M. Langman, G. Renard, P. Dighiero; Topical Cyclosporine a 2% in Patients With Severe Ocular Rosacea After Penetrating Keratoplasty: A 3 Years Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4274.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To evaluate cyclosporine A (CsA) 2% eye-drops in the prevention of acute rejection after penetrating keratoplasty (PKP) in patients with severe ocular rosacea.

Methods:: IRB approval (Poitiers School of Medicine) was given an Informed Consent was obtained from all patients according to French Regulations. 35 patients with severe Rosacea that underwent a PKP from 2000 to 2003 for pseudophakic bullous keratopathy were topically treated with CsA. The patient’s charts, the level of rejection risk, the IOP and the graft outcome were analyzed.

Results:: No systemic effect was detected. 21 rejections developed after a median of 18.5 months. Ten rejections under CsA treatment were reversible.

Conclusions:: CsA 2% eye-drops are not an effective treatment in the prevention of acute rejection in patients with severe ocular rosacea.

Keywords: anterior segment • cornea: clinical science • cyclosporine 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept